- Title
- A phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies
- Creators
- Dale SCHAAR - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United StatesLauri GOODELL - Department of Pathology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, United StatesJacqueline MANAGO - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United StatesYONG LIN - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United StatesEric H RUBIN - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United StatesAllan CONNEY - Laboratory of Cancer Research, Rutgers University, Piscataway, NJ, United StatesRoger K STRAIR - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United StatesJoseph AISNER - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United StatesXIAO XING CUI - Laboratory of Cancer Research, Rutgers University, Piscataway, NJ, United StatesZHENG TAO HAN - Henan Tumor Research Institute, Zheng Zhou, Henan, ChinaRichard CHANG - Laboratory of Cancer Research, Rutgers University, Piscataway, NJ, United StatesJohn MARTIN - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United StatesStephanie GROSPE - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United StatesLiesel DUDEK - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United StatesJoan RILEY - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, United States
- Publication Details
- Cancer chemotherapy and pharmacology, Vol.57(6), pp.789-795
- Date published
- 2006
- Publisher
- Springer
- Academic Unit
- Biostatistics (SHP); Pathology and Laboratory Medicine (RWJMS); Blood and Marrow Transplant Program; Lung Cancer/Thoracic Oncology Program
- Language
- English
- Resource Type
- Journal article
- Identifiers
- 991031654798704646
Journal article
A phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies
Cancer chemotherapy and pharmacology, Vol.57(6), pp.789-795
2006
PMID: 16231182
Metrics
20 Record Views